Clec12a (also called myeloid inhibitory C-type lectin-like receptor, MICL) was originally described as an ITIM-containing inhibitory CLR expressed by human granulocytes and monocytes. It was suggested that Clec12a recognizes some endogenous ligands as soluble Clec12a could bind to single-cell suspensions isolated from various murine tissues. CLEC12A is a myeloid lineage antigen that is highly expressed by AML cells and LSCs, but not expressed by normal hematopoietic stem cells (HSCs), thus minimizing off-target toxicity.